M
Margit Serban
Researcher at Boston Children's Hospital
Publications - 51
Citations - 629
Margit Serban is an academic researcher from Boston Children's Hospital. The author has contributed to research in topics: Haemophilia & Haemophilia B. The author has an hindex of 9, co-authored 47 publications receiving 539 citations. Previous affiliations of Margit Serban include Romanian Academy.
Papers
More filters
Journal ArticleDOI
Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors.
Cindy A. Leissinger,Alessandro Gringeri,Bülent Antmen,Erik Berntorp,Chiara Biasoli,Shannon L. Carpenter,Paolo Cortesi,Hyejin Jo,Kaan Kavakli,Riitta Lassila,Massimo Morfini,Claude Negrier,Angiola Rocino,Wolfgang Schramm,Margit Serban,Marusia Valentina Uscatescu,Jerzy Windyga,Bulent Zulfikar,Lorenzo G. Mantovani +18 more
TL;DR: AICC prophylaxis at the dosage evaluated significantly and safely decreased the frequency of joint and other bleeding events in patients with severe hemophilia A and factor VIII inhibitors.
Journal ArticleDOI
Recombinant factor VIIa analog in the management of hemophilia with inhibitors: Results from a multicenter, randomized, controlled trial of vatreptacog alfa
Steven R. Lentz,Silke Ehrenforth,F. Abdul Karim,Tadashi Matsushita,K. N. Weldingh,Jerzy Windyga,J. N. Mahlangu,A. Weltermann,E. de Paula,M. Cerqueira,Silva Zupančić-Šalek,O. Katsarou,Marina Economou,Laszlo Nemes,Zoltán Boda,Elena Santagostino,Giuseppe Tagariello,Hideji Hanabusa,Katsuyuki Fukutake,M. Taki,Midori Shima,M. Gorska-Kosicka,Margit Serban,T. Andreeva,Aleksandar Savic,I. Elezovic,Johnny Mahlangu,W. Tsay,M. Shen,Ampaiwan Chuansumrit,Pantep Angchaisuksiri,Kaan Kavakli,A. Kupesiz,I. Sasmaz,Bella Madan,Savita Rangarajan,Paul L. F. Giangrande,K. Saxena,S. Lentz,Michael Recht,Christine L. Kempton,J. Barrett,G. Young,Doris Quon,A. Stopeck,J. Lin,Afshin Ameri,Shipra Kaicker,Philip Kuriakose,D. Obzut,M. Wang,I. Ortiz,A. Sori +52 more
TL;DR: Vatreptacog alfa, a recombinant factor VIIa (rFVIIa) analog with three amino acid substitutions and 99% identity to native FVIIa, was developed to improve the treatment of hemophilic patients with inhibitors.
Journal ArticleDOI
Genetic and demographic features of X-linked agammaglobulinemia in Eastern and Central Europe: A cohort study
Beáta Tóth,Alla Volokha,Alexander Mihas,Małgorzata Pac,Ewa Bernatowska,Irina Kondratenko,A. V. Polyakov,Melinda Erdos,Srdjan Pasic,Michaela Bataneant,Anna Szaflarska,Kristina Mironska,Darko Richter,Katarina Stavrik,Tadej Avcin,Gabriella Marton,K. Nagy,Beata Derfalvi,Miklós Szolnoky,A Kalmár,Michael Belevtsev,Marina N. Guseva,Aurica Rugina,Gergely Kriván,L. Timar,Zoltán Nyul,Bernadett Mosdósi,Lidija Kareva,Sonja Peova,Liudmyla Chernyshova,Ioan Gherghina,Margit Serban,Mary Ellen Conley,Luigi D. Notarangelo,C. I. Edvard Smith,Jacques J.M. van Dongen,Mirjam van der Burg,László Maródi +37 more
TL;DR: The BTK gene was sequenced from the genomic DNA of patients with a high susceptibility to infection, almost no CD19(+) peripheral blood B cells, and low or undetectable levels of serum immunoglobulins M, G, and A, compatible with a clinical and immunological diagnosis of XLA.
Journal ArticleDOI
Haemophilia care in Europe: the ESCHQoL study.
W. Schramm,Alessandro Gringeri,Rolf Ljung,Karin Berger,Alexander Crispin,Monika Bullinger,Paul L. F. Giangrande,S. von Mackensen,Lorenzo G. Mantovani,László Nemes,Margit Serban +10 more
TL;DR: Statistical analysis revealed that residence in areas with low factor consumption/availability is the most prominent risk factor for joint disease and access of European patients with haemophilia to optimal care with safe factor VIII concentrates is limited and depends on the region of residence.
Journal ArticleDOI
Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity.
Johnny Mahlangu,K. N. Weldingh,Steven R. Lentz,Shipra Kaicker,Faraizah Abdul Karim,Tadashi Matsushita,Michael Recht,W. Tomczak,Jerzy Windyga,Silke Ehrenforth,K. Knobe,Ansgar Weltermann,E. de Paula,M. Cerqueira,Silva Zupančić-Šalek,Olga Katsarou,Marina Economou,László Nemes,Zoltán Boda,Elena Santagostino,Giuseppe Tagariello,Hideji Hanabusa,Katsuyuki Fukutake,Midori Shima,Margit Serban,Ivo Elezovic,Aleksandar Savic,Ming Shen,Ampaiwan Chuansumrit,Pantep Angchaisuksiri,Kaan Kavakli,Ilgen Sasmaz,Bella Madan,Paul L. F. Giangrande,Christine L. Kempton,Guy Young,Doris Quon,Afshin Ameri,Philip Kuriakose,Dana Obzut,Michael Wang,Idith Ortiz +41 more
TL;DR: In a randomized, double‐blind, crossover, confirmatory phase III trial (adept™2), 8/72 (11%) hemophilia A or B patients with inhibitors treated for acute bleeds developed anti‐drug antibodies (ADAs) to vatreptacog alfa.